Gastric Cancer: Dostarlimab Immunotherapy Study

We are exploring a new treatment approach for patients with localized gastric cancer to see if delaying surgery while using Dostarlimab can be effective. The study aims to evaluate patient responses and safety over time.

>2 years ≤5 visits Efficacy phase (II)No Placebo Investigational Medicines InjectionGastroenterologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Dostarlimab

Dostarlimab is a monoclonal antibody that helps the immune system attack certain cancers by blocking a protein that restrains immune response.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Jemperli

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Centre Hospitalier Universitaire De Bordeaux

Oncologie Digestive

Canéjan, France

Centre Hospitalier Universitaire Reims

HEPATO-GASTRO-ENTEROLOGIE ET CANCEROLOGIE DIGESTIVE

Cormontreuil, France

Assistance Publique Hopitaux De Paris

Oncologie

Créteil, France

Sponsor: Gercor

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.